Trial Profile
Phase II Trial of Iodine-131 Anti-B1 Antibody for Previously Untreated, Advanced Stage, Low Grade Non-Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Tositumomab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 31 Jul 2012 Actual patient number changed from 76 to 77 as reported by ClinicalTrials.gov.
- 03 Jul 2012 Primary endpoints identified as reported by ClinicalTrials.gov.
- 20 Apr 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.